Published in Br J Pharmacol on December 24, 2009
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis (2014) 1.88
Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog (2011) 1.29
Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther (2010) 1.14
Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. Cancer Chemother Pharmacol (2012) 1.14
Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Model Mech (2012) 1.09
Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration. Xenobiotica (2011) 1.04
Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. Ther Adv Musculoskelet Dis (2010) 1.02
Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs (2014) 1.00
Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study. Health Qual Life Outcomes (2013) 0.98
The future of uveitis treatment. Ophthalmology (2013) 0.92
Promising new treatments for psoriasis. ScientificWorldJournal (2013) 0.91
New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Des Devel Ther (2013) 0.89
Inhibition of phosphodiesterase-1 attenuates cold-induced pulmonary hypertension. Hypertension (2013) 0.88
Pathogenesis of Behçet's disease: autoinflammatory features and beyond. Semin Immunopathol (2015) 0.88
[Treatment of posterior noninfectious uveitis : Current situation and future developments]. Ophthalmologe (2016) 0.87
Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide. Br J Pharmacol (2012) 0.87
A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol (2012) 0.86
Inhibition of phosphodiesterase-4 promotes oligodendrocyte precursor cell differentiation and enhances CNS remyelination. EMBO Mol Med (2013) 0.84
Cyclic AMP regulates the migration and invasion potential of human pancreatic cancer cells. Mol Carcinog (2013) 0.84
Cyclic AMP dysregulates intestinal epithelial cell restitution through PKA and RhoA. Inflamm Bowel Dis (2011) 0.84
Nitric oxide/cGMP pathway signaling actively down-regulates α4β1-integrin affinity: an unexpected mechanism for inducing cell de-adhesion. BMC Immunol (2011) 0.82
Attenuation of TNF production and experimentally induced inflammation by PDE4 inhibitor rolipram is mediated by MAPK phosphatase-1. Br J Pharmacol (2013) 0.81
Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases. Dermatol Ther (Heidelb) (2013) 0.81
Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Res Ther (2015) 0.81
Biologics in dermatology. Pharmaceuticals (Basel) (2013) 0.80
Alterations in cyclic nucleotide phosphodiesterase activities in omental and subcutaneous adipose tissues in human obesity. Nutr Diabetes (2011) 0.79
Isothiocyanates inhibit psoriasis-related proinflammatory factors in human skin. Inflamm Res (2012) 0.79
Recent advances in understanding psoriasis. F1000Res (2016) 0.79
Psoriatic arthritis and psoriasis: differential diagnosis. Clin Rheumatol (2016) 0.76
The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma. BMC Pulm Med (2014) 0.76
Apremilast Use for Moderate-to-Severe Atopic Dermatitis in Pediatric Patients. Case Rep Dermatol (2016) 0.76
Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases. J Thorac Dis (2017) 0.75
Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis. Rheumatol Ther (2014) 0.75
A Role for cAMP and Protein Kinase A in Experimental Necrotizing Enterocolitis. Am J Pathol (2016) 0.75
Immunotargeting in the management of psoriasis. Immunotargets Ther (2013) 0.75
Apremilast. Hosp Pharm (2014) 0.75
Current and potential immune therapies and vaccines in the management of psoriasis. Hum Vaccin Immunother (2014) 0.75
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease. J Am Assoc Nurse Pract (2016) 0.75
Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast. BioDrugs (2015) 0.75
Clinical potential of apremilast in the treatment of psoriatic arthritis. Immunotargets Ther (2014) 0.75
The effects of apremilast on the QTc interval in healthy male volunteers: a formal, thorough QT study. Int J Clin Pharmacol Ther (2016) 0.75
Differential gene and protein expression of chemokines and cytokines in synovial fluid of patients with arthritis. Arthritis Res Ther (2016) 0.75
New Oral Therapies for Psoriasis: A Comprehensive Review. J Clin Aesthet Dermatol (2016) 0.75
Impact of Renal Impairment on the Pharmacokinetics of Apremilast and Metabolite M12. Clin Pharmacol Drug Dev (2016) 0.75
Cytokine modulators in the treatment of sarcoidosis. Rheumatol Int (2011) 0.75
Pathogenesis and therapy of psoriasis. Nature (2007) 6.94
Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem (2007) 5.62
Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev (2004) 3.65
Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today (2005) 3.20
Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol (2005) 2.83
Dermal injection of immunocytes induces psoriasis. J Clin Invest (1996) 2.64
TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol (2005) 2.29
PDE4 inhibitors: current status. Br J Pharmacol (2008) 2.23
cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. Circ Res (2007) 2.21
Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet (2005) 2.02
The granulocyte-macrophage colony-stimulating factor/interleukin 3 locus is regulated by an inducible cyclosporin A-sensitive enhancer. Proc Natl Acad Sci U S A (1993) 2.01
Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A-mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1). Br J Pharmacol (2002) 1.85
Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription. J Immunol (1997) 1.82
PGE(1) stimulation of HEK293 cells generates multiple contiguous domains with different [cAMP]: role of compartmentalized phosphodiesterases. J Cell Biol (2006) 1.81
CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol (2006) 1.77
Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol (2009) 1.62
Purification and properties of the insulin-stimulated cyclic AMP phosphodiesterase from rat liver plasma membranes. Biochem J (1981) 1.58
Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. Biochem J (1997) 1.51
An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin (2008) 1.49
Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. Differential modulation of B7-1 (CD80) and B7-2 (CD86) expression. J Immunol (1995) 1.27
Transcription factors and asthma. Eur Respir J (1998) 1.23
Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai. Naunyn Schmiedebergs Arch Pharmacol (1991) 1.23
Arrestin times for compartmentalised cAMP signalling and phosphodiesterase-4 enzymes. Curr Opin Cell Biol (2005) 1.22
Psoriasis: dysregulation of innate immunity. Br J Dermatol (2005) 1.18
Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov (2005) 1.17
Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol (2006) 1.16
Natural killer and natural killer-T cells in psoriasis. Arch Dermatol Res (2002) 1.09
Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol (2008) 1.06
Alternative splicing of cAMP-specific phosphodiesterase mRNA transcripts. Characterization of a novel tissue-specific isoform, RNPDE4A8. J Biol Chem (1996) 1.05
Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3. Biochem J (1997) 1.04
Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model. Am J Pathol (1995) 1.04
Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells. Br J Pharmacol (2004) 1.04
Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators. J Immunol (1995) 1.03
Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett (1998) 1.01
Dynamic regulation, desensitization, and cross-talk in discrete subcellular microdomains during beta2-adrenoceptor and prostanoid receptor cAMP signaling. J Biol Chem (2007) 1.01
Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pig. Br J Pharmacol (1994) 1.01
Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol (2004) 1.01
cAMP elevators inhibit LPS-induced IL-12 p40 expression by interfering with phosphorylation of p38 MAPK in murine peritoneal macrophages. Cell Res (2002) 0.98
Psoriasis is mediated by a cutaneous defect triggered by activated immunocytes: induction of psoriasis by cells with natural killer receptors. J Invest Dermatol (2002) 0.95
Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol (1996) 0.95
cAMP phosphodiesterase-4A1 (PDE4A1) has provided the paradigm for the intracellular targeting of phosphodiesterases, a process that underpins compartmentalized cAMP signalling. Biochem Soc Trans (2006) 0.93
Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis. J Pharmacol Exp Ther (2005) 0.92
Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol. Br J Pharmacol (1998) 0.91
Molecular cloning and expression of a human phosphodiesterase 4C. Cell Signal (1997) 0.90
Phosphodiesterase 4 inhibitors and inflammatory bowel disease: emerging therapies in inflammatory bowel disease. Expert Opin Investig Drugs (2007) 0.89
Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther (2004) 0.89
Calcitonin gene-related peptide inhibits lipopolysaccharide-induced interleukin-12 release from mouse peritoneal macrophages, mediated by the cAMP pathway. Immunology (2000) 0.88
Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes. Cell Biochem Biophys (1998) 0.87
PDE4 inhibitors - a review of the current field. Prog Med Chem (2009) 0.86
Ustekinumab: a new option in psoriasis therapy. Drugs (2009) 0.84
The induction of terminal differentiation markers by the cAMP pathway in human HaCaT keratinocytes. Skin Pharmacol Appl Skin Physiol (1998) 0.84
A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology (2006) 0.83
Rolipram, a phosphodiesterase 4 inhibitor, prevented cancellous and cortical bone loss by inhibiting endosteal bone resorption and maintaining the elevated periosteal bone formation in adult ovariectomized rats. J Musculoskelet Neuronal Interact (2007) 0.83
Ro 20-1724: an agent that significantly improves psoriatic lesions in double-blind clinical trials. J Invest Dermatol (1979) 0.80
The role of calcium/calmodulin-dependent protein kinase cascade on MIP-1alpha gene expression of ATL cells. Exp Hematol (2008) 0.80
Cilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease. Ann Pharmacother (2006) 0.79
CC-10004 . Curr Opin Investig Drugs (2005) 0.78
In vitro T cell response to staphylococcal enterotoxin B superantigen in chronic plaque type psoriasis. Acta Derm Venereol (1995) 0.78
Potent inhibition of cytokine production from intestinal lamina propria T cells by phosphodiesterase-4 inhibitory thalidomide analogues. J Clin Immunol (2001) 0.77
Identification of phosphodiesterase IV activity and its cyclic adenosine monophosphate-dependent up-regulation in a human keratinocyte cell line (HaCaT). J Invest Dermatol (1995) 0.77
The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell (1996) 17.13
Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst (2000) 14.43
The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A (1997) 8.27
The soluble methane mono-oxygenase of Methylococcus capsulatus (Bath). Its ability to oxygenate n-alkanes, n-alkenes, ethers, and alicyclic, aromatic and heterocyclic compounds. Biochem J (1977) 7.57
Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science (2000) 4.87
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood (2001) 4.76
The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells. J Exp Med (1992) 4.58
The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature (1999) 4.55
CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J Immunol (2000) 4.41
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood (2000) 4.37
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol (1999) 3.99
Infectious human herpesvirus 8 in a healthy North American blood donor. Lancet (1997) 3.93
Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. Immunity (1996) 3.91
A TATA box implicated in E1A transcriptional activation of a simple adenovirus 2 promoter. Nature (1987) 3.81
Evaluation of PCR-generated chimeras, mutations, and heteroduplexes with 16S rRNA gene-based cloning. Appl Environ Microbiol (2001) 3.76
Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal center-localized subset of CXCR5+ T cells. J Exp Med (2001) 3.71
Validation of 1989 Tennessee birth certificates using maternal and newborn hospital records. Am J Epidemiol (1993) 3.67
Thymic dendritic cells and T cells develop simultaneously in the thymus from a common precursor population. Nature (1993) 3.48
Normal p21N-ras couples bombesin and other growth factor receptors to inositol phosphate production. Nature (1986) 3.41
The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med (2001) 3.39
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol (2004) 3.37
Functions of the MDM2 oncoprotein. Cell Mol Life Sci (1999) 3.35
Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med (1996) 3.33
The Cataract National Dataset electronic multicentre audit of 55,567 operations: risk stratification for posterior capsule rupture and vitreous loss. Eye (Lond) (2008) 3.32
Consensus statement on the live organ donor. JAMA (2000) 3.29
Chronic-disease classification in evaluation of medical care programs. Med Care (1969) 3.23
Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet (1994) 3.12
Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. Science (2001) 3.11
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia (2012) 3.04
Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother (1997) 2.98
Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol (2007) 2.95
Rules of chemokine receptor association with T cell polarization in vivo. J Clin Invest (2001) 2.87
mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. EMBO J (2001) 2.86
The association between the quality of inpatient care and early readmission. Ann Intern Med (1995) 2.86
Molecular cloning and expression of the mouse ornithine decarboxylase gene. Proc Natl Acad Sci U S A (1984) 2.83
Search for a resonance decaying into WZ boson pairs in pp collisions. Phys Rev Lett (2010) 2.83
Early T lymphocyte progenitors. Annu Rev Immunol (1996) 2.81
The development, maturation, and turnover rate of mouse spleen dendritic cell populations. J Immunol (2000) 2.76
Nitrite reductase genes (nirK and nirS) as functional markers to investigate diversity of denitrifying bacteria in pacific northwest marine sediment communities. Appl Environ Microbiol (2000) 2.72
Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. Proc Natl Acad Sci U S A (1999) 2.71
Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax (2005) 2.69
Preparation and hybridization analysis of DNA/RNA from E. coli on microfabricated bioelectronic chips. Nat Biotechnol (1998) 2.69
Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest (1997) 2.68
Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis (1996) 2.68
6-C-kine (SLC), a lymphocyte adhesion-triggering chemokine expressed by high endothelium, is an agonist for the MIP-3beta receptor CCR7. J Cell Biol (1998) 2.62
Structural analysis of a set of proteins resulting from a bacterial genomics project. Proteins (2005) 2.59
A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet (1996) 2.59
Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir. J Nucl Med (1998) 2.58
Immobilization of Notch ligand, Delta-1, is required for induction of notch signaling. J Cell Sci (2000) 2.57
Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol (2001) 2.53
A cohort study of summary reports of controlled trials. JAMA (1990) 2.51
A SNP resource for human chromosome 22: extracting dense clusters of SNPs from the genomic sequence. Genome Res (2001) 2.49
CCR7 expression and memory T cell diversity in humans. J Immunol (2001) 2.42
The incidence of perioperative myocardial infarction in men undergoing noncardiac surgery. Ann Intern Med (1993) 2.41
Neutralization of Clostridium difficile toxin by Clostridium sordellii antitoxins. Infect Immun (1978) 2.39
Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J Virol (1998) 2.38
Simultaneous recovery of RNA and DNA from soils and sediments. Appl Environ Microbiol (2001) 2.38
The Cataract National Dataset electronic multi-centre audit of 55,567 operations: updating benchmark standards of care in the United Kingdom and internationally. Eye (Lond) (2007) 2.35
Male pseudohermaphroditism caused by mutations of testicular 17 beta-hydroxysteroid dehydrogenase 3. Nat Genet (1994) 2.35
Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst (1999) 2.34
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia (2001) 2.30
Cholesterol is excluded from the phospholipid annulus surrounding an active calcium transport protein. Nature (1975) 2.30
Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. The San Francisco community prophylaxis trial. N Engl J Med (1990) 2.29
Myc requires distinct E2F activities to induce S phase and apoptosis. Mol Cell (2001) 2.29
A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5. J Virol (1998) 2.28
Incidence of fractures compared to cardiovascular disease and breast cancer: the Women's Health Initiative Observational Study. Osteoporos Int (2008) 2.27
Co-metabolism. Philos Trans R Soc Lond B Biol Sci (1982) 2.27
Identification of a novel E2F3 product suggests a mechanism for determining specificity of repression by Rb proteins. Mol Cell Biol (2000) 2.24
Activation of two signal-transduction systems in hepatocytes by glucagon. Nature (1986) 2.21
A new human p53 homologue. Nat Med (1998) 2.21
Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther (1999) 2.21
SPTLC1 is mutated in hereditary sensory neuropathy, type 1. Nat Genet (2001) 2.20
Impact of neonatal vitamin A supplementation on infant morbidity and mortality. J Pediatr (1996) 2.19
Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res (2001) 2.18
Detection of novel splicing patterns in a HPV16-containing keratinocyte cell line. Virology (1990) 2.17
Properties of the methane mono-oxygenase from extracts of Methylosinus trichosporium OB3b and evidence for its similarity to the enzyme from Methylococcus capsulatus (Bath). Eur J Biochem (1979) 2.16
A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi's sarcoma-associated herpesvirus. J Virol (1999) 2.16
A peripheral and an intrinsic enzyme constitute the cyclic AMP phosphodiesterase activity of rat liver plasma membranes. Biochem J (1980) 2.14
Bifunctional imidoesters as cross-linking reagents. Biochem Biophys Res Commun (1966) 2.14
Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood (1994) 2.14
"Masonry arch" model of the spine. Spine (Phila Pa 1976) (1989) 2.13
MIRACLE: mass isotopomer ratio analysis of U-13C-labeled extracts. A new method for accurate quantification of changes in concentrations of intracellular metabolites. Biotechnol Bioeng (2004) 2.12
Expression cloning of the STRL33/BONZO/TYMSTRligand reveals elements of CC, CXC, and CX3C chemokines. J Immunol (2001) 2.12
Periodic patterns of actin turnover in lamellipodia and lamellae of migrating epithelial cells analyzed by quantitative Fluorescent Speckle Microscopy. Biophys J (2005) 2.11
Premarket evaluation of a commercial glycoprotein G-based enzyme immunoassay for herpes simplex virus type-specific antibodies. J Clin Microbiol (1998) 2.10
Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc Natl Acad Sci U S A (1999) 2.08
Perioperative on-site haemoglobin determination: as accurate as laboratory values? Can J Anaesth (1996) 2.08
The glucagon receptor of rat liver plasma membrane can couple to adenylate cyclase without activating it. Biochim Biophys Acta (1976) 2.07
Non-O:1 Vibrio cholerae bacteremia: case report and review. Rev Infect Dis (1988) 2.07
Annular lipids determine the ATPase activity of a calcium transport protein complexed with dipalmitoyllecithin. Biochemistry (1976) 2.06
Utilization of C-C chemokine receptor 5 by the envelope glycoproteins of a pathogenic simian immunodeficiency virus, SIVmac239. J Virol (1997) 2.04
Is an early calcium flux necessary to stimulate lymphocytes? Nature (1977) 2.03
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer (2002) 2.03
Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry. J Immunol Methods (2001) 2.01